Canopy Growth Corporation

NasdaqGS:CGC Rapport sur les actions

Capitalisation boursière : US$376.9m

Canopy Growth Croissance future

Future contrôle des critères 0/6

Canopy Growth devrait augmenter ses bénéfices et ses revenus de 36.5% et de 11.2% par an respectivement, tandis que le BPA devrait croître de croître de 71.9% par an.

Informations clés

36.5%

Taux de croissance des bénéfices

71.89%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices14.4%
Taux de croissance des recettes11.2%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour27 Apr 2026

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Seeking Alpha • Apr 23

Canopy Growth Rallies On Renewed Hope Of Cannabis Rescheduling

Summary Canopy Growth rallied yesterday on news that the Trump administration may reschedule cannabis soon. The entire cannabis sector experienced a rally over the day. The development does not tell us when it will happen nor how it will happen. The current rally may subside once there are no further developments. I continue my rating of a Hold. Read the full article on Seeking Alpha
Seeking Alpha • Apr 22

Canopy Growth: Zombie Financials As Delisting Threat Looms

Summary Canopy Growth is down substantially year-to-date as the company files to issue and sell $200 million more worth of its common shares. Dilution for the last 3 years is 177%. Free cash flow for CGC's most recent quarter remains negative, but like net income, the figure has seen some improvement over its year-ago figure. The company now barely sits above the $1 minimum listing price required by the NASDAQ. Read the full article on Seeking Alpha
Seeking Alpha • Mar 30

Cannabis Investors Should Sell Canopy Growth

Summary Canopy Growth's stock has plummeted over 99% from its peak, facing severe financial challenges, including significant debt and a massive increase in shares outstanding. Despite some potential for a rebound, the stock's valuation remains unattractive, with an enterprise value to projected adjusted EBITDA ratio of 85X for FY26. Better investment alternatives in the cannabis sector include Village Farms, Organigram, Tilray Brands, and Cronos Group, which offer superior valuations and operational performance. I am upgrading Canopy Growth stock to Sell from Strong Sell, but recommend exploring other cannabis stocks or ancillary companies like GrowGeneration for better opportunities. Read the full article on Seeking Alpha
Seeking Alpha • Feb 17

Canopy Growth: Q3 Earnings Shows Improvement But Cannabis Sector Remains Weak

Summary Canopy Growth recently reported improved Q3-2025 financial results. They expect continued growth across operating segments. The company's stock price is down 46% over the last twelve months. Investor sentiment continues to be weak on the cannabis sector. I continue my rating of a Hold. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Canopy Growth: Still A Disaster Heading Into Fiscal Q3 Results

Summary Canopy Growth Corporation is likely to report weak financials when reporting FQ3 results on February 7. The company struggles with low gross margins of 35% and continues to burn cash, while a peer's results support strong growth in the international medical cannabis business. The recent acquisitions of Acreage Holdings and Wana Brands may boost revenue, but the profit picture remains bleak, with a new CEO likely to restructure the business. Investors should be cautious; despite potential revenue growth, CGC stock's outlook hinges on improved margins and positive EBITDA, which remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Jan 22

Crashing Canopy Growth Is Still Not A Buy

Summary Canopy Growth's stock has plummeted over 90% in a decade, with further declines expected due to ongoing financial struggles and lack of U.S. market progress. Despite potential short-term gains from filling price gaps, Canopy Growth remains a Strong Sell due to its unprofitability and high debt levels. Constellation Brands is unlikely to buy Canopy Growth, given its previous failed investment and current financial structure. There are better investment opportunities in cannabis stocks, both in Canadian LPs like Organigram and Village Farms, and U.S. MSOs like Cresco Labs and Verano Holdings. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Canopy Growth Remains Undervalued Amidst Cannabis Sector Uncertainty

Summary Canopy Growth is down 46% over the last twelve months and hit its 52-week low on Friday. The company recently reported in-line financial results and positive outlook. The cause of the downtrend concerns uncertainty around cannabis regulation in the US. The greater stock market is undergoing extreme volatility and the cannabis sector remains weak. I continue my previous rating of a Hold and believe markets will settle in February. Read the full article on Seeking Alpha
Seeking Alpha • Nov 10

Avoid Canopy Growth

Summary Canopy Growth's stock has significantly declined due to high debt, negative cash flow, and underwhelming financial performance, with a potential to drop to $1. The company's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Despite some improvement in adjusted EBITDA, Canopy Growth's valuation is too high compared to peers like Organigram and Cronos Group. Investors should consider better-valued and financially stronger cannabis stocks, as Canopy Growth's outlook remains bleak amidst ongoing financial struggles. Read the full article on Seeking Alpha
Seeking Alpha • Oct 05

Canopy Growth: Weak Fundamentals And Growth Acceleration Challenges

Summary Canopy Growth faces significant financial challenges, including a stressed balance sheet, high debt, and potential equity dilution, making it an unattractive investment. Despite initial excitement over potential cannabis rescheduling, the long-term impact on growth is uncertain, leading to renewed stock correction. Canopy's revenue is declining, with limited growth in international markets and reduced R&D and advertising expenses, further hindering growth prospects. Given the high valuation and ongoing regulatory headwinds, I recommend a "Sell" rating for Canopy Growth, favoring companies with stronger financial flexibility. Read the full article on Seeking Alpha
Seeking Alpha • Aug 27

Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End High

Summary Canopy Growth Corporation stock rallied to $15 due to the DEA's proposal to reschedule cannabis, but this timeline has now been extended to 2025. CEO David Klein, who oversaw a 97% stock decline, is set to exit in March 2025 and has started selling shares. Klein's share sales were related to tax liabilities from vested restricted stock units, leaving him with 360,829 shares. Canopy Growth faces significant liquidity issues, holding $143 million in cash and short-term investments as of June 30, 2024. Read the full article on Seeking Alpha
Seeking Alpha • Jun 17

Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold)

Summary Canopy Growth recently reported improved financial performance for Q4-2024. Canopy USA has acquired US THC cannabis assets and plans to acquire more. The company expects an increase in demand for its international cannabis exports. Canopy Growth's stock price is down this month, but recently experienced a sustained rally on news of cannabis rescheduling in the US. I continue my previous rating of a Hold and unpack the risks. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Canopy Growth: Another Ugly Cannabis Report

Summary Canopy Growth Corporation's weak financial results have caused its stock to trade lower, leading to a loss of investor interest. The company reported another disastrous quarter with a weak adjusted gross margin, a large net loss, and negative adjusted EBITDA. The stock has an EV topping $1 billion, which is mismatched with the weak financial results. Read the full article on Seeking Alpha
Seeking Alpha • Apr 26

Canopy Growth Set For U.S. Cannabis Markets

Summary Canopy Growth has received shareholder approval for its plans to enter the US THC cannabis market. The company's recent Q3-2024 report shows ongoing financial recovery and success of the company's new right-sizing strategy. Canopy Growth's stock price has been on an ongoing uptrend, gaining 87% over the last three months. I change my previous rating of Canopy Growth from a buy to a hold. Read the full article on Seeking Alpha
Seeking Alpha • Mar 22

Canopy Growth Is Climbing, But It Won't Last

Summary Canopy Growth's shares have risen by 28% in the past month due to the potential rescheduling of cannabis in the U.S. However, the company is facing operational and financial challenges, with persistent cash flow difficulties and declining sales growth. The company's low valuation does not make it an attractive investment, and its future outlook remains bleak. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come

Summary Canopy Growth stock has fallen recently due to a dilutive secondary offering and ongoing financial troubles. With $411 million in net debt, I expect more dilution to come moving forward. Investors may be betting on a federal rescheduling of cannabis, but that is unlikely to benefit the company. I reiterate my strong sell rating for CGC stock due to the myriad of negative fundamental factors. Read the full article on Seeking Alpha
Seeking Alpha • Jan 29

Canopy Growth: Further Implosion Is Now A Matter Of When Not If

Summary Canopy Growth has reduced its free cash burn to CAD$67 million per quarter for an implied cash runway of five quarters against its current short-term liquidity position. Three institutional shareholders are looking to exit their positions, reducing their aggregate ownership from 13.4% to 2.5%. A high debt burden and elevated cash burn will drive continued near-term dilution for shareholders. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Avoid Canopy Growth After Failed Equity Sale

Summary Canopy Growth's stock has declined 82.6% since I predicted a decline last January, much more than the market. The company's plan to transform into an American cannabis operator has not helped its stock performance. The recent decline in stock price was due to an equity offering announced by Canopy Growth early in the week. After the close on Friday, though, the deal was cancelled. Canopy Growth should be trading 50% lower. Read the full article on Seeking Alpha

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:CGC - Estimations futures des analystes et données financières antérieures (CAD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
3/31/2029420N/AN/AN/A1
3/31/2028387-131-66-614
3/31/2027368-126-62-565
3/31/2026288-143-88-705
12/31/2025278-327-87-79N/A
9/30/2025279-387-96-88N/A
6/30/2025275-516-133-124N/A
3/31/2025269-604-177-166N/A
12/31/2024277-477-163-155N/A
9/30/2024280-586-167-160N/A
6/30/2024287-602-191-185N/A
3/31/2024297-484-286-282N/A
12/31/2023293-999-407-400N/A
9/30/2023299-991-520-511N/A
6/30/2023317-1,025-576-566N/A
3/31/2023333-3,079-568-558N/A
12/31/2022367-3,051-559-544N/A
9/30/2022423-2,938-583-568N/A
6/30/2022466-2,766-550-521N/A
3/31/2022476-255-594-546N/A
12/31/2021557-428-587-517N/A
9/30/2021569-1,223-552-437N/A
6/30/2021572-1,244-644-513N/A
3/31/2021547-1,745-622-466N/A
12/31/2020506-2,348-803-579N/A
9/30/2020477-1,535-1,033-681N/A
6/30/2020419-1,244-1,282-733N/A
3/31/2020399-1,321-1,495-773N/A
12/31/2019385-415-1,610-802N/A
9/30/2019344-256N/A-709N/A
6/30/2019291-832N/A-626N/A
3/31/2019226-736N/A-535N/A
12/31/2018155-398N/A-332N/A
9/30/201894-464N/A-257N/A
6/30/201888-148N/A-137N/A
3/31/201878-67N/A-82N/A
12/31/201770-21N/A-60N/A
9/30/201758-19N/A-41N/A
6/30/201749-13N/A-36N/A
3/31/201740-8N/A-27N/A
12/31/201630-1N/A-14N/A
9/30/201624-7N/A-15N/A
6/30/201618-8N/A-14N/A
3/31/201613-3N/A-14N/A
12/31/201580N/A-14N/A
9/30/201561N/A-12N/A
6/30/20153-5N/A-10N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CGC devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CGC devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CGC devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CGC ( 11.2% par an) devrait croître plus lentement que le marché de US ( 11.6% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CGC ( 11.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CGC devrait être élevé dans 3 ans

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/20 07:51
Cours de l'action en fin de journée2026/05/20 00:00
Les revenus2025/12/31
Revenus annuels2025/03/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Canopy Growth Corporation est couverte par 23 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Cormark
Jesse PytlakATB Cormark Historical (Cormark Securities)